Polaryx Therapeutics, Inc. (PLYX) shareholders
Close on Nov 17, 2026Market cap $79.75MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Alex Keun Mo Yang Joint filing with Mstone Partners Healthcare Limited (47.40%) | 22,744,796 | 48.00% | 13D (active) | Jan 29, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of PLYX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 1,657,872 | 3.33% | $4.41M | −516 | 0.00% |
| Geode Capital Management, LLC | 170,998 | 0.34% | $455.08K | +325 | 0.00% |
| Vanguard Fiduciary Trust Co | 105,072 | 0.21% | $279.49K | +516 | 0.00% |
| Hrt Financial LP | 82,094 | 0.16% | $218.00K | New | 0.00% |
| State Street Corp | 58,104 | 0.12% | $154.56K | – | 0.00% |
| BlackRock, Inc. | 41,012 | 0.08% | $109.09K | – | 0.00% |
| Jane Street Group, LLC | 31,441 | 0.06% | $83.63K | New | 0.00% |
| Northern Trust Corp | 27,987 | 0.06% | $74.45K | – | 0.00% |
| Allworth Financial LP | 7,727 | 0.02% | $20.55K | New | 0.00% |
| Vanguard Global Advisers, LLC | 6,318 | 0.01% | $16.81K | – | 0.00% |
| Tower Research Capital LLC (TRC) | 3,002 | 0.01% | $7.99K | +1,221 | 0.00% |
| UBS Group AG | 1,283 | 0.00% | $3.41K | −12,196 | 0.00% |
| Fortitude Family Office, LLC | 189 | 0.00% | $503 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 13 | 2M | 4.4% | 4 / 3 | 2 / 5 | 0M | 0M |
| Q1 2026 | 14 | 2M | 4.5% | 14 / 0 | 0 / 0 | 2M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of PLYX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,468,014 | 2.95% | $3.90M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 142,033 | 0.28% | $377.81K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 67,079 | 0.13% | $219.35K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 28,648 | 0.06% | $93.68K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 26,450 | 0.05% | $86.49K | 0.00% | May 31, 2026 |
| Vanguard Balanced Index Fund | 25,969 | 0.05% | $69.08K | 0.00% | Jun 30, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 21,856 | 0.04% | $58.14K | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 19,605 | 0.04% | $64.11K | 0.00% | May 31, 2026 |
| Total Stock Market Index Trust | 865 | 0.00% | $2.30K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Alex Keun Mo Yang | Chief Executive Officer, Director, 10% owner | – | – | May 28, 2026 |
| G. Michael Landis | Chief Financial Officer, Director | 228,225 | 0.46% | Feb 20, 2026 |
| Lisa Bollinger | Chief Medical Officer | 150,358 | 0.30% | Jan 29, 2026 |
| Andrew John O | Chief Investment Officer | 471,808 | 0.95% | Jan 29, 2026 |
| Partners Healthcare Ltd Mstone | Director, 10% owner | 25,633,249 | 51.42% | May 28, 2026 |
| III Francis A. Braun | Director | – | – | Jan 29, 2026 |
| Mitchel Berger | Director | – | – | Jan 29, 2026 |
| Charles S. Ryan | Director | – | – | Jan 29, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Partners Healthcare Ltd Mstone Director, 10% owner | May 27, 2026 | Buy | +88,453 | $4.07 | $360.00K | 24,233,249 |
| G. Michael Landis Chief Financial Officer, Director | Feb 18, 2026 | Buy | +2,867 | $2.79 | $8.00K | 228,225 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 9 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Polaryx Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 5,911 shares on Aug 27, 2026 over the last 90 days.
See a number that looks wrong?